CIK 0001754068
- Non-accelerated filer
- Smaller reporting company
Kalaris Therapeutics, Inc.
Sign in to watch- Ticker
- KLRS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831971007
- Phone
- +1 650-249-2727
- Business address
- 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
- Former names
- Allovir, Inc., ViraCyte, Inc.
- 4 Derivatives Options or other derivatives
- 4 Grant or award Director acquired 11,444,503 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Sinha Vikas sold 303 shares at $10.08 ($3,053)
- 4 Open-market sale Chief Accounting Officer sold 96 shares at $10.08 ($967)
- 4 Open-market sale General Counsel sold 106 shares at $10.08 ($1,068)
- 4 Open-market sale General Counsel sold 52 shares at an average $9.50 ($494)
- 4 Open-market sale Chief Accounting Officer sold 36 shares at an average $9.51 ($342)
- 4 Open-market sale Sinha Vikas sold 129 shares at an average $9.50 ($1,226)
- 4 Open-market sale General Counsel sold 409 shares at $0.44 ($180)
- 4 Open-market sale Chief Accounting Officer sold 332 shares at $0.44 ($146)
- 4 Open-market sale Sinha Vikas sold 979 shares at $0.44 ($431)
- 4 Gift General Counsel gave 57,549 shares (gift)
Page 3 of 19 · 363 filings